Isoliquiritigenin: A Unique Component That Attenuates Adipose Tissue Inflammation and Fibrosis by Targeting the Innate Immune Sensors by Nagai, Yoshinori et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Isoliquiritigenin: A Unique Component That
Attenuates Adipose Tissue Inflammation and Fibrosis
by Targeting the Innate Immune Sensors
Yoshinori Nagai, Yasuharu Watanabe,
Hiroe Honda and Kiyoshi Takatsu
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/66727
Abstract
Recent studies have suggested that pattern recognition receptors, including inflammasomes
and TLRs, in the innate immune system recognize various kinds of endogenous ligands and
have critical roles in initiating or promoting obesity-associated chronic inflammation. These
findings have provided new therapeutic strategies based on regulation of the innate
immune system. With the rapid advancement of novel technologies and the increased
research on natural products, many new plant-derived extracts and active compounds have
been identified to exhibit anti-inflammatory effects. Isoliquiritigenin (ILG) is a flavonoid
derived from Glycyrrhiza uralensis with a chalcone structure. We have reported that ILG
inhibits NLRP3 inflammasome activation resulting in the improvement of diet-induced
adipose tissue inflammation and insulin resistance. Furthermore, we have also demon-
strated that ILG improves diet-induced fibrosis in adipose tissue by inhibiting TLR4- and
Mincle-induced expression of fibrosis-related genes in obese adipose tissue and macro-
phages. Thus, ILG can suppress two important dysfunctions of obesity, adipose tissue
inflammation and fibrosis by targeting innate immune sensors. Here we overview ILG as
a potential therapeutic agent for the treatment of obesity-associated diseases. We also
summarize anti-inflammatory actions of other constituents of licorice.
Keywords: chronic inflammation, diabetes, inflammasome, innate immunity, meta-
bolic syndrome
1. Introduction
Obesity has become a worldwide health problem because it is strongly associated with meta-
bolic syndromes including type 2 diabetes mellitus (T2DM), atherosclerosis and ischemic heart
diseases [1, 2]. Accumulating evidence indicates that chronic low-grade inflammation has a
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crucial role in the pathogenesis of obesity-associated metabolic dysfunction [3, 4]. The chronic
inflammatory alternations are associated with dynamic changes in the composition and func-
tion of immune cells in various tissues such as adipose tissue, pancreatic islet, liver, muscle,
and hypothalamus [57]. A large number of inflammatory immune cells infiltrate into adipose
tissue during the course of obesity. M1-like macrophages, an inflammatory type of macro-
phage, accumulate in adipose tissue and are major sources of inflammatory mediators such as
tumor necrosis factor (TNF)-α and IL-6 [8].
The connective fiber content of adipose tissue dramatically increases by the upregulation of
collagen expression, which in turn elevates the overall rigidity of adipose tissue and finally
leads to fibrosis. The deficiency of collagen 6, a key component of the extracellular matrix in
adipose tissue, significantly improves the phenotypes of obese mice, including adipocyte
death and adipose tissue inflammation [9]. This implies that alterations in the extracellular
matrix in adipose tissue are linked to the development of inflammation. Thus, inflammation
and fibrosis are important targets for the treatment of obesity.
An obese state results in an elevation of circulating levels of fatty acids (FAs) and, subse-
quently, an increase in inflammation of adipose tissue [10]. Adipose macrophages play critical
roles in the immune responses through several FA-sensing mechanisms, such as pattern
recognition receptors (PRRs). PRRs such as toll-like receptors (TLRs) and nucleotide oligomer-
ization domain (NOD)-like receptors (NLRs) quickly recognize pathogenic agents [11]. It is
now becoming even more apparent that these PRRs are not only able to recognize microbial
components but also mediate immune responses to endogenous molecules, including those
arising in metabolic disorders, such as FAs. These endogenous molecules have been termed
danger-associated molecular patterns (DAMPs) and have similar functions as microbial com-
ponents to activate immune responses [12]. In the obese state, TLR4 may be activated by
saturated free FAs, such as palmitic acid, derived from hypertrophied adipocytes as a DAMP
and promote adipose tissue inflammation and insulin resistance [1315]. Inflammasomes are
multimeric protein complexes that are crucial for caspase-1, IL-1β, and IL-18 production [16].
The nucleotide-binding domain, leucine-rich repeats containing family, pyrin domain-
containing-3 (NLRP3) inflammasome also senses obesity-associated FAs and contributes to
obesity-induced inflammation and insulin resistance [17, 18]. Moreover, IL-1β inhibits insulin
signaling in the insulin-target organs, including adipose tissue, liver, and skeletal muscle, and
also induces dysfunction and cell death of insulin-producing pancreatic β cells [19]. Macro-
phage-inducible C-type lectin (Mincle) recognizes not only cord factor, a mycobacterial glyco-
lipid, but also SAP130 released from dead cells [20, 21]. Furthermore, Mincle is highly
expressed in M1 macrophages in adipose tissue and involved in the induction of adipose tissue
fibrosis and insulin resistance during obesity [22, 23].
Plant-derived natural products and their derivatives or synthetic mimics make up a consider-
able portion of current drugs. These products have played an important role in treating T2DM,
especially in Asian countries. We previously reported that glycyrrhizin (GL) and isoliquir-
itigenin (ILG), components of Glycyrrhiza uralensis (G. uralensis), inhibit TLR4 signaling at the
receptor level on the cell surface, resulting in inhibition of NF-κB and mitogen-activated
protein kinases (MAPKs) activation [24]. Furthermore, ILG potently inhibits NLRP3
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inflammasome activation independent of its inhibitory action on TLR4 [25]. Our in vivo study
revealed that ILG attenuated high-fat diet (HFD)-induced adipose tissue inflammation and
insulin resistance by inhibiting NLRP3 inflammasome activation in adipose tissue [25]. In
addition to inflammation, we recently reported that ILG impacts fibrogenesis in adipose tissue
by targeting TLR4 and Mincle activation in macrophages. On the basis of these findings,
natural products derived from G. uralensis may serve as lead compounds for the development
of new anti-T2DM drugs.
This review article highlights the recent discoveries of the anti-inflammatory and anti-fibrotic
effects and mechanisms of action of G. uralensis components that target PRRs. We will also
overview our findings that ILG targets activation of TLR4, NLRP3 inflammasome, and Mincle.
We will discuss the roles of innate immunity and potential mechanisms by which it partici-
pates in obesity-associated inflammation and fibrosis.
2. PRRs that link with adipose tissue inflammation and fibrosis
2.1. Toll-like receptors
TLRs are transmembrane proteins that recognize conserved structural moieties of microorgan-
isms and for the subsequent induction of pro-inflammatory responses [26]. They directly bind
to their ligands and activate the NF-κB and MAPK pathways to induce the production of pro-
inflammatory cytokines that are important for evading pathogens. It is widely suggested that
TLRs also sense non-microbial endogenous ligands, such as dietary FAs [12]. Activation of
TLRs by the endogenous ligands similarly induces pro-inflammatory pathways as microbial
ligands in various organs, such as adipose tissue and the liver.
TLR4 is the most important TLR for LPS-mediated inflammatory responses [27]. There is a
body of evidence suggesting that TLR4 is an attractive candidate for linking innate immune
responses to obesity-associated dysfunction. For example, TLR4 expression is increased in
inflammatory macrophages derived from obese adipose tissue [13, 28]. TLR4 KO mice or mice
with a loss-of-function mutation in the TLR4 gene are protected from obesity-associated
insulin resistance [13, 29]. Furthermore, hematopoietic cell-specific deletion of TLR4 amelio-
rates HFD-induced hepatic insulin resistance [30]. Intriguingly, saturated FAs released by
adipocyte lipolysis can be endogenous TLR4 ligands and activate the NF-κB pathway on
macrophages [15]. Another paper reported that resistin derived from adipose tissue directly
bound to TLR4 in the hypothalamus and leads to the activation of MAPKs signaling and
promoting insulin resistance through MyD88 [31], suggesting that resistin is an endogenous
TLR4 ligand, which links hypothalamic inflammation with insulin resistance.
We previously demonstrated that the development of obesity-related inflammation required
radioprotective 105 (RP105) rather than TLR4 [32]. RP105 was identified as a first mammalian
homologue of Drosophila toll that expressed on B cells [33] and suggested to be involved in
LPS-induced B-cell responses. In fact, RP105-deficient mice show reduced LPS-dependent
proliferation and CD86 upregulation in B cells, albeit to a lesser extent than TLR4-deficient
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mice [34, 35]. Among B cell subsets, marginal zone (MZ) B cells express high density of RP105.
We have showed that RP105 is indispensable for TLR4-dependent plasma cell differentiation
and IgM production in MZ B cells [36]. Additionally, M1 macrophages of murine epididymal
white adipose tissue (eWAT) highly express RP105 [32]. This expression is markedly increased
by HFD supplementation [32]. Furthermore, HFD-induced obesity, adipose tissue inflamma-
tion, and insulin resistance are severely attenuated in RP105 KO mice compared with wild-
type (WT) and TLR4 KOmice. In contrast to TLR4, RP105 is not activated by palmitic acid [32].
Our results suggest that ligands and signaling pathways involved in RP105-mediated adipose
tissue inflammation do not completely overlap with those utilized by TLR4. Future investiga-
tions will determine an endogenous ligand and a signaling pathway of RP105 in adipose
tissue.
2.2. NLRP3 inflammasome
Inflammasomes are cytoplasmic receptors and play an important role in the host defense
against microbial infection. Activation of NLRP3 inflammasome is regulated by various sterile
stimuli, including cholesterol crystals, β-amyloid, palmitic acid, and ceramides. It is generally
accepted that two signals are required for NLRP3 inflammasome activation. One is an NF-κB-
dependent priming step that induces the transcription of pro-IL-1β and NLRP3. Another is an
activation step that induces the activation of caspase-1. Normal activation of NLRP3
inflammasome contributes to host defense, but several studies suggest that excessive activa-
tion leads to the development of obesity-associated inflammation.
Islet amyloid polypeptide (IAPP) is deposited in the pancreas and associated with the loss of β
cell function in T2DM. The observation of NLRP3-dependent IL-1β production by macro-
phages in response to IAPP implied a potential role for NLRP3 in promoting IL-1β secretion
in T2DM [37]. Interestingly, an anti-diabetic drug glyburide inhibits NLRP3 activation by
macrophages in response to IAPP. Direct involvement of NLRP3 in obesity has been confirmed
in studies that NLRP3 KO mice fed HFD display reduced caspase-1 activation and pro-IL-1β
expression in adipose tissue compared with WTmice [38].
2.3. C-type lectin Mincle
C-type lectin receptors elicit inflammation and innate immune responses through activation of
multiple signaling cascades. Mincle recognizes cord factor, a mycobacterial glycolipid, and
transduces activation signals by associating with the Fc receptor common γ-chain, which
contains immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic
domain. The phosphorylated ITAM recruits Syk (spleen tyrosine kinase), leading to activation
of NF-κB and MAP kinases [39, 40].
The expression level of Mincle is increased by various cellular stresses and stimuli. Mincle
expression is upregulated in patients with rheumatoid arthritis and is increased in microglia,
neuron, and endothelial cells in the brain after ischemic stroke [41, 42]. Furthermore, Mincle is
highly expressed in inflammatory M1 macrophages in adipose tissue and involved in the
induction of adipose tissue fibrosis and insulin resistance [22, 23]. These results suggest that
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Mincle is involved in the pathogenesis of various inflammation and represents a potential
target molecule for the treatment of inflammatory diseases, including rheumatoid arthritis,
brain infarction, and T2DM.
3. Natural products that target innate immune system
Chinese herbal formulas with anti-diabetic effects are well developed such that a number of
these formulas have commonly been used in diabetic patients since ancient times. The most
frequently used 10 Chinese herbs in the period from 2004 to 2009, for the treatment of T2DM,
include Radix Astragali, Rhizome Dioscoreae, Radix Rehnabbiae, Radix Salviae Miltiorrhizae, Radix
Puerariae, Rhizoma Coptidis, Fructys Lycii, Poria, Rhizoma Alismatis, and Fructus Corni [43].
However, it is unclear whether these Chinese herbs have as potent anti-inflammatory effects
as those of Western anti-diabetic drugs.
Glycyrrhiza plants (licorice) have been used as herbal medicine worldwide for over 4000 years
[44]. Several studies have reported that Chinese and Japanese herbal medicines or their com-
ponents regulate innate immunity. Among Glycyrrhiza plants, G. uralensis is one of the most
used herbal medicines in Asian countries. Various components have been isolated from lico-
rice, for example triterpene saponins, flavonoids, isoflavonoids, and chalcones. Therefore, we
have focused on the anti-inflammatory effects of G. uralensis and its components on innate
immune responses.
3.1. Glycyrrhizin
Glycyrrhizin (GL), a triterpene saponin, is considered to be the major biological active ingredi-
ent of G. uralensis. It has been reported that GL inhibits LPS-induced TLR4 internalization [45].
Our experiments confirmed that GL suppressed lipid A moiety of LPS-induced IL-6 produc-
tion in mouse macrophages [24]. Furthermore, GL treatment significantly suppressed the
production of inflammatory cytokines, including TNF-α and IL-6, in LPS-injected mice [24].
We further demonstrated that GL attenuated lipid A-mediated activation of NF-κB and
MAPKs, including JNK, p38, and ERK. It was suggested that GL might be incorporated into
lipid bilayers and suppress the plasma membrane integrity [45]. LPS binds to MD-2 and this
triggers homodimerization of the TLR4/MD-2 complex, resulting in the induction of signal
transduction [46]. Our data demonstrated that GL inhibited LPS binding to the complex in a
dose-dependent manner. Accordingly, LPS-induced TLR4 homodimerization was suppressed
by GL stimulation. Moreover, GL inhibited not only LPS- but also TLR9 ligand CpG-DNA-
induced inflammatory responses (our unpublished data), as suggested previously [45]. Thus,
GL inhibits the activation of multiple TLRs at the plasma membrane by altering membrane
integrity.
GL also inhibits the activation of another PRR, NLRP3 inflammasome, induced by various
stimuli, including adenosine triphosphate (ATP), monosodium urate (MSU) and nigericin [25].
LPS is a potent inducer of the priming of the NLRP3 inflammasome. However, the inhibitory
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activity of GL on NLRP3 inflammasome is independent of its effect on TLR4 activation [25].
Intriguingly, activation of another inflammasome, absent in melanoma 2 (AIM2)
inflammasome, was suppressed by GL stimulation [25], suggesting that GL inhibits multiple
inflammasomes activation. However, a high concentration of GL is required for these inhibi-
tory effects on inflammasomes. Therefore, GL may not be suggested to be a potential thera-
peutic agent for the treatment of obesity-associated inflammation.
3.2. Isoliquiritigenin
ILG, another component of G. uralensis, is a flavonoid with a chalcone structure. It has a wide
variety of biological activities, including anti-allergic, anti-tumor growth, and anti-platelet
aggregation activity. We recently demonstrated that ILG potently inhibited activation of both
TLR4/MD-2 and NLRP3 inflammasome [24, 25]. ILG significantly suppressed LPS-induced
production of inflammatory cytokines not only in vitro but also in vivo [24]. Whereas GL
stimulation affects the binding of LPS to TLR4/MD-2, the amount of bound LPS was not
decreased by ILG stimulation. However, LPS-induced homotypic interaction of TLR4 was
potently inhibited by ILG stimulation in a dose-dependent manner. Additionally, ILG
blocked lipid A-induced NF-κB and MAPKs activation [24]. This may be due to the inhibi-
tion of TLR4 homodimerization. Beside this, it has been reported that ILG interacts with IKK
directly and inhibits its kinase activity [47]. Thus, ILG suppresses TLR4/MD-2-mediated
immune responses in multiple steps, at the receptor level and the downstream signaling
level (Figure 1).
3.2.1. Inhibitory effects of isoliquiritigenin on PRR-mediated adipose tissue inflammation
In addition to the inhibitory effects of ILG on the TLR4/MD-2 complex, we demonstrated that
it was highly effective in inhibiting NLRP3 inflammasome activation by various stimuli includ-
ing ATP, MSU, and nigericin [25]. These responses were suppressed by a low concentration of
ILG (10∼30 μM). The IC50 for the inhibitory effect of ILG is 0.4936 μM. Furthermore, ILG was
more effective in inhibiting NLRP3 inflammasome activation than GL (IC50, 358.9 μM) and
parthenolide, a known inhibitor of NLRP3 inflammasome. Contrary to GL, ILG did not inhibit
poly(dA:dT)-induced activation of the AIM2 inflammasome. As ILG suppresses NLRP3- but
not AIM2-induced formation of ASC pyroptosome, it is unlikely that ASC is a molecular target
of ILG. IAPP is a unique polypeptide constituent of amyloid deposited in pancreatic islets
[48, 49]. This deposition is associated with disease progression of T2DM and triggers NLRP3
inflammasome activation in islet macrophages [37]. The sulfonylurea drug glyburide inhibits
IAPP-induced activation of NLRP3 inflammasome [37]. It is noteworthy that a low concentra-
tion of ILG is more effective in inhibiting IAPP-induced activation of NLRP3 inflammasome
than that of glyburide [25] (Figure 1).
The above observations led us to investigate the inhibitory effects of ILG on TLR4- and NLRP3-
associated inflammation in obesity. ILG supplementation remarkably improved obesity,
hyperlipidemia, hepatic steatosis, and insulin resistance in HFD-fed wild-type mice [25].
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Furthermore, ILG supplementation inhibited IL-1β and caspase-1 production in eWAT from
wild-type mice fed with HFD for 4 weeks. At this time point, TNF-α production was not
increased in eWAT from HFD-fed mice compared with that from normal diet-fed mice. Thus,
inflammasome activation occurs in eWAT at an early time point during obesity before TNF-α-
associated inflammation.
Because ILG inhibits the priming and activation steps of the inflammasome via TLR4 and
NLRP3, respectively, the therapeutic effects of ILG on HFD-induced adipose tissue inflamma-
tion and insulin resistance may be attributed to the inhibition of not only NLRP3 but also TLR4
pathways. Indeed, TLR4 is shown to have a critical role in the pathogenesis of obesity-induced
inflammation using TLR4-deficient mice [13, 29]. Therefore, ILG is a potential therapeutic
agent that targets NLRP3- and TLR4-associated adipose tissue inflammation in obesity.
Figure 1. Schematic diagram of ILG-mediated suppression of PRR activation in macrophage. NLRP3 inflammasome
is activated by various DAMPs, including IAPP and free FAs. The inflammasomes assemble into oligomeric
complex with ASC and activate caspase-1. Activated caspase-1 processes pro-IL-1β into mature IL-1β. ILG potently
inhibits IAPP-induced NLRP3 inflammasome activation. The LPS sensor TLR4/MD-2 also recognizes free FAs such
as palmitic acid. ILG inhibits TLR4/MD-2-induced inflammation and fibrogenic responses in multiple steps, at the
receptor level and the downstream signaling level. Mincle recognizes a mycobacterial glycolipid TDM, also named
cord factor. TDM-stimulated inflammatory and fibrogenic responses are attenuated by ILG treatment. Because
HFD-induced adipose tissue inflammation and fibrosis are greatly improved in Mincle-deficient mice compared
with WT mice, it is suggested that Mincle may recognize an endogenous ligand derived from inflamed tissues,
resulting in the induction of inflammation and fibrosis.
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3.2.2. Inhibitory effects of isoliquiritigenin on PRR-mediated adipose tissue fibrosis
In addition to inflammation, fibrosis may have an important role in adipose tissue dysfunction
[9]. Because TLR4 signaling in immune cells has a key role in the development of obesity- and
endotoxin-mediated adipose tissue fibrosis [50], we examined whether ILG attenuated TLR4-
stimulated expression of fibrosis-related genes in peritoneal macrophages and stromal vascu-
lar fraction (SVF) of obese eWAT. Lipid A stimulation increased the expression of fibrosis-
related genes, such as TGF-β and TIMP-1 (tissue inhibitor of metalloproteinase-1) in these cells.
These increases were significantly attenuated by ILG stimulation (Figure 1).
Mincle stimulation is also crucial for fibrogenesis in SVF of obese adipose tissue [22]. The SVF
from HFD-fed mice was stimulated with a Mincle ligand trehalose-6,6-dimycolate (TDM), a
mycobacterial cell wall glycolipid [22, 51]. TDM stimulation significantly increased TIMP-1
and PDGF-B mRNA expression in the SVF and these increases were significantly attenuated
by ILG stimulation [51] (Figure 1).
Finally, we examined whether ILG improved HFD-induced adipose tissue fibrosis. Histologi-
cal analysis revealed that HFD treatment induced extensive interstitial fibrosis in eWAT, which
was markedly suppressed by ILG supplementation (0.5% w/w in HFD) [51]. HFD treatment
increased collagen 1, TGF-β, TIMP-1, and PDGF-B mRNA expression in eWAT. These expres-
sions were markedly decreased by ILG supplementation. These results highlight that ILG is a
promising therapeutic candidate for HFD-induced adipose tissue fibrosis by suppressing the
activation of innate immune sensors.
4. Concluding remarks
It has now become clear that G. uralensis-derived components including ILG have a major
impact in innate immunity to prevent adipose tissue inflammation and fibrosis. On the
other hand, ILG also acts on adipocytes, and consequently suppresses inflammatory
changes elicited by macrophage-derived mediators such as TNF-α [51], suggesting that
ILG targets multiple cells that constitute adipose tissue. Moreover, activation of various
innate immune sensors is affected by ILG stimulation, consequently suppressing adipose
tissue inflammation and fibrosis. A better understanding of these mechanisms will be
addressed in the near future. With these new findings, we will be enabled to design better
therapeutic strategies based on innate immunity through the usage of ILG to combat
obesity-associated diseases.
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